Methods for treating and managing pain in a patient with therapeutic neuromodulation and associated systems and methods are disclosed herein. Chronic or debilitating pain can be associated, for example, with a disease or condition of the abdominal or reproductive viscera. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a target blood vessel of a diseased or damaged organ of a patient experiencing pain. Targeted sympathetic nerve activity can be modulated at least along afferent pathways which can improve a measurable parameter associated with the pain of the patient The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

A system for electro-therapeutically treating a patient includes a stimulatory device electromagnetically coupled with the nervous system of a patient, an electrical power supply, and a control mechanism structured to energize the stimulatory device by way of the electrical power supply at a stimulation frequency. The control mechanism is further structured to control the energizing so as to produce a treatment signal encoded in the energizing and having a treatment signal frequency equal to or less than the stimulation frequency.

Systems, devices, methods, and kits for monitoring one or more physiologic and/or physical signals from a subject are disclosed. A system including a head mounted display to monitor one or more physiologic signals from the face or head of the subject is disclosed. A method for analyzing an ocular parameter of the subject to determine a sympathetic and a parasympathetic outflow thereto is disclosed.

Method and system for monitoring the autonomic nervous system (ANS) of a subject, comprising acquiring at least one physiological signal having W heartbeats, generating data which is a function of the variability of the heart rate on the W heartbeats, with the HRV having W1 RR intervals separating two consecutive heartbeats detected respectively at the moments tk1 and tk, each RR interval having a duration of value a=tt1 with k=(XW+2) . . . X; calculating at least one parameter taken from the parameter TAS(tx) representing the level of activity of the sympathetic system and/or the parameter TAP(tx) representing the level of activity of the parasympathetic system; and/or other parameters such as the parameter SL(tx) representing stress level of the subject at the moment tx and calculated using the equation such that SL(tx)=100+TAS(tx)TAP(tx); and supplying data representative of at least one parameter.

A system for monitoring patient intake includes an acquisition and transmission device having an electrode configured to detect vagus nerve activity. A first internal inductive coil is configured to communicate a signal indicative of the vagus nerve activity detected by the electrode to a second external inductive coil. The system also includes a processor configured to execute instructions stored in a memory that cause the system to process the signal received by the second induction coil into data corresponding to intake of the patient and communicate the data to a server that is accessible by a clinician.

A monitoring system may include a processor and display system for displaying results from the monitoring. A user may be in a sterile field away from the processor and display system and selected input devices. A controller may be physically connected to the monitoring system from the sterile field to allow the user to control the monitoring system.

A device for neurostimulation including an electrode structure for delivering stimulation pulses to a nerve as well as for processing and extracting evoked compound action potentials, wherein the electrode structure comprises at least a first anode, at least a second anode opposing the first anode and a plurality of cathodes arranged between said anodes, wherein said cathodes are asymmetrically arranged with respect to said at least first and second anode to permit evoked compound action potential sensing via the anode electrodes simultaneously with stimulation.

An example system includes an analyzer to identify first activity in first neuro-response data, the first activity generated in response to exposure of a subject to a first stimulus prior to exposure to an advertisement or entertainment; identify second activity in second neuro-response data, the second activity generated in response to re-exposure of the subject to the first stimulus after to exposure to the advertisement or entertainment; calculate a differential event related potential measurement; and calculate a differential event related power spectral perturbation. The example system includes a resonance estimator to determine a subject resonance measurement to the advertisement or the entertainment based on the differential event related potential measurement and adjust at least one of the subject resonance measurement or the differential event related potential measurement based on the differential event related power spectral perturbation to generate an adjusted subject resonance measurement.

Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

A monitoring system and method for detecting an infection or for assessing a suitability of neuromodulation therapy for a patient. R-R intervals of a patient are detected and stored for a first time period. A heart rate variability (HRV) of the stored R-R intervals is determined using at least one of a time domain analysis, an entropy analysis, a frequency domain analysis, a wavelet analysis, or a detrended fluctuation analysis. The patient is identified as exhibiting symptoms of a systemic infection and/or identified as suitable for neuromodulation therapy if the HRV is higher than a first threshold.